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The global burden of cancer is rising at an alarming rate. It remains as one of the top 
causes of morbidity and mortality worldwide. It is predicted that within 2020, there will be 
15 million new cases of cancer in the world, with cancer-related deaths increasing to 12 
million. According to the World Health Organization (WHO), the global cancer burden is 
expected to surge 57% worldwide in the next 20 years. A significant rise in cancer 
burden will occur in the low-income and middle-income (developing) countries not only 
due to demographic shifts, but also by the transition of risk factors due to globalization of 
economies and behavioral patterns mirroring high-income economies (developed 
countries). The rise in global cancer burden and the urgency to fight against cancer has 
lead to cancer control being termed as a “global health priority. This alarming rise in 
cancer burden will require a renewed attention for control, prevention and early detection 
of cancer that can complement the improved treatments. The understanding of the 
global trends and regional and socio-economic variations of cancer incidence and 
mortality would help global health workforce design strategies for prevention, early 
detection and develop unified global and region-specific plans to coordinate and improve 
health care environment and patient health.  
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Chapter I 
INTRODUCTION 
An overview of global cancer burden as a global health priority  
According to the World Health Organization (WHO), the global cancer burden is 
expected to surge 57% worldwide in the next 20 years. This alarming rise in cancer 
burden will require a renewed attention for control, prevention and early detection of 
cancer that can complement the improved treatments. The rise in global cancer burden 
and the urgency to fight against cancer has lead to cancer control being termed as a 
“global health priority”. 1-5 
The total number of deaths associated with cancer reached 8 million in 2010, 
which correlates to about 15% of all deaths worldwide.6 It has been estimated that 33% 
to 50% of cancers can be prevented through control or avoidance of known risk factors.7 
Additionally, a significant proportion of the remaining 50% of cancer related deaths could 
be prevented through early detection and effective treatment strategies. Therefore as 
noted by Drs. Ilbawi and Anderson2, it is critical to prioritize cancer interventions in the 
global health agenda in which non-communicable diseases (NCDs) including cancer 
receive less than 3% of the total donor development assistance for health ($503 Million 
out of $22 Billion per year).2 Epidemiological data obtained from developed (higher-
income) countries indicate that the prevention and early detection programs have been 
somewhat successful at decreasing cancer deaths.8 However, the real challenge and 
difficulty has been the translation of these prevention and early detection programs to 
less developed (low-and middle-income) countries. Some of the major hurdles faced in 
these countries include less effective health care system and lack of cancer awareness, 
competing health priorities, use of carcinogens, low funding for health care reforms and 
limited health care workforce with specialized training.9 In the less developed nations, 
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65% of the cancer-related deaths occur annually, however the global health resources 
directed towards these countries constitute only about 5%.  
Global heath priority of cancer control is designed towards three primary goals: i) 
prevention of preventable cancer ii) cure of curable cancer and iii) palliate cancers for 
which prevention and/or cure is not achieved.2 Cancer affects all regions and 
communities worldwide. However, the prevalence and type of cancer shows marked 
variation among communities. As discussed above, the total burden of cancer remains 
highest in the affluent countries, but the low-and middle-income countries are narrowing 
that gap at a very rapid pace. As the low-and middle-income countries succeed in 
attaining the lifestyle of higher-income countries, they will face with increased cancer 
burden.   
It is important for global health workforce to understand the global burden of 
cancer. Several factors lead to the “globalization” of cancer.10 The rapid aging of 
population is increasing the cancer burden. Other critical factors include diet, tobacco 
and use of harmful substances and infectious agents. The understanding of the global 
trends and regional and socio-economic variations would help global health leadership 
design strategies for prevention, early detection and develop unified global and region-
specific strategies to coordinate and improve health care environment and patient 
health. The Human Development Index (HDI) is an important classifier for the 
globalization of cancer.11 The HDI takes into account education, life expectancy and 
national income to categories countries into one of four levels of human development: 
low, medium, high and very high. It is well known that the communicable diseases and 
nutrition related disorders are still the most common causes of death in low-HDI 
countries. However, the projections are that NCDs, including cancer, will overtake the 
communicable diseases and nutrition related diseases by 2030.12 The projected 
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increase in global cancer burden—from 12·7 million new cases in 2008, to 22·2 million 
by 2030 —indicates population growth and an evolving age distribution together with 
other important changes in underlying incidence, allied to the prevalence and distribution 
of risk factors. 
The key points related to the global cancer burden is highlighted below: 
• In 2012, there were >14 million new cancer cases and >8 million cancer deaths. Figures 
1, 2 and 3 shows the worldwide distribution of incidence, mortality and prevalence of 
cancer. Table 1 lists the global cancer burden with the current incidence and mortality 
rates for all cancers across the world. Table 2a,b shows the global burden of different 
cancers for both sexes, all ages combined. Table 3 shows the global cancer burden 
(incidence and mortality) for all cancers across the world and the more developed and 
less developed regions of the world. It is observed that the more developed regions have 
higher cancer burden compared to less developed regions.  
• For women, breast cancer was the leading cancer globally and in developed and 
developing countries.  
• For men, lung cancer was the leading cancer globally and in developed and developing 
countries.  
• For men, incident cases have increased the most for prostate cancer at the global 
setting and in developed and developing countries.  
• For women at the global level, incident cases have increased the most for non-Hodgkin 
lymphoma; in developed countries, incident cases have increased the most for kidney 
cancer; in developing countries, incident cases have increased the most for breast 
cancer. 
• More developed regions have higher incidence of cancer compared to less developed 
regions. 
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In the following chapters, we will discuss prediction or time trends in pancreatic 
and liver cancer with respect to geographic locations; socio-economic status and 
demographic shift using the well-defined predictions from GLOBOCAN 2012 across 
geographical and socio-economical divide. Pancreatic cancer (PC) is a lethal 
malignancy that accounts for about 4% of cancer-related deaths in both males and 
females worldwide.13-24 In the United States, PC accounts for about 2.7% of all new 
cancer cases and is projected to become the second largest cause of cancer-related 
deaths by 2030.25 Liver cancer (LC) is fast developing into a global medical crisis26. 
Historically, LC has been most prevalent in the developing regions of Southeast Asia 
and Africa. This high burden of LC in these developing regions has been mainly 
attributed to Hepatitis B virus (HBV) and exposure to aflotoxin27. However, in recent 
years, developed Western countries have witnessed an alarming rise in LC partly due to 
increased Hepatitis C virus (HCV) infection and non-communicable diseases (NCD) 
associated with alcohol use and non-alcoholic steatohepatitis (NASH)26. LC is the fifth 
most common cancer and the third leading cause of cancer-related deaths globally26,27. 
Although the trends in the incidence and mortality of PC and LC are well studied in the 
United States and some Western European countries, the same cannot be said for the 
rest of the world. There are few publications on PC and LC originating from regions of 
low incidence or resource-poor areas of the world.28 Similarly, there is a scarcity of 
reports describing the overall global trends in the incidence and mortality of PC and LC 
across all regions of the world and encompassing all strata of socio-economic 
development.  
 
Conclusion:  
Prediction and time trends of the number of cases of incidence and mortality is quite 
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relevant for health care planning purposes and allocation of available resources. The 
demographic shift towards elder age groups worldwide and select geographic regions 
over the next two decades is likely to contribute to an increase in cancer burden for 
many cancer sites.  
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Figure 1: Worldwide age-adjusted Incidence for all cancer excluding non-
melanoma skin cancer for both sexes  
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Figure 2: Worldwide age-adjusted mortality for all cancer excluding non-
melanoma skin cancer for both sexes  
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Figure 3: Worldwide age-adjusted prevalence for all cancer excluding non-
melanoma skin cancer for both sexes  
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Table 1 below shows the global cancer burden with the current incidence and 
mortality rates for all cancers across the world.  
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Table 2(a-b) below shows the global burden of different cancers for both sexes, all 
ages combined.  
 
Table 2a:  
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Table 2b:  
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Table 3 below shows the global cancer incidence and mortality rates for all 
cancers across the world and the more developed and less developed regions for 
both male and female.  
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Chapter II 
METHODS 
GLOBOCAN 2012 
We utilized the GLOBOCAN 2012 database for obtaining data relating to the 
incidence and mortality for PC for all regions of the world. GLOBOCAN 2012 is a 
database that is maintained by the International Agency for Research on Cancer (IARC) 
that compiles estimates of incidence and mortality for 27 major types of cancer. This 
data includes information on all cancers that is stratified by gender for 184 countries and 
30 world regions.29The detailed methodology used for the GLOBOCAN 2012 estimates 
can be accessed via GLOBOCAN webpage30 and Ferlay et al (2015).29  
 
World Health Organization (WHO) Regions  
For the purposes of the study we utilized the geographic regions of the world 
described by the WHO. The six WHO regions are: The WHO African Region (AFRO; 
Region 1), WHO Region of the Americas (PAHO; Region 2), WHO Eastern 
Mediterranean Region (EMRO; Region 3), WHO European Region (EURO; Region 4), 
WHO South-East Asian Region (SEARO; Region 5), and WHO Western Pacific Region 
(WPRO; Region 6). Detailed information can be found at WHO website with alphabetical 
listing of the WHO Member States31  
 
Human Development Index (HDI) 
To account for the varying socio-economic standing of different countries/regions 
of the world we adhered to the model of Human Development Index. The HDI been 
	   14 
developed by the United Nations Development Programme (UNDP) provides a summary 
measure of human development based on three fundamental areas of human 
development: 1) life expectancy at birth, 2) adult literacy rate and primary education to 
tertiary education enrolment rates, and 3) GDP per head adjusted for purchasing-power 
parity [US$]).11 HDI uses complex statistical combinations to rank countries (187) into 
four tiers of human development (from 0 to 1).11,32 The four tiers of human development 
include: countries with very high HDI (HDI≥0.800; VHHD), countries with a high HDI 
(HDI≥0.700; HHD), Medium HDI countries (HDI≥0.550; MHD), and countries with a low 
HDI (HDI<0.550; LHD).  
 
Age Standardized Rate (ASR) 
The Age Standardized Rate (ASR) is the measurement of the rate of distribution 
of population it would have if it had a standard age structure. The risk of developing 
cancer is highly influenced by age and therefore standardization is necessary when 
comparing several populations that differ with respect to age. The ASR data for all 
analysis were obtained from GLOBOCAN 2012 database.29 
 
Demographic Shift 
Demographic shift (also referred as population ageing) is the shift in the 
proportion of older population globally with the decline in fertility and increase in life 
expectancy.33 This shift in population ageing is expected to have a profound effect on 
cancer burden.29 The number of older persons (ages 60 and over) is the fastest growing 
globally and is projected to be approximately 1.4 billion by 2030.33 
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Statistical Analysis 
R and SAS software (SAS Institute Inc., Cary, NC, USA) were used for statistical 
analysis. Linear regression was used to evaluate trends in total incidence and mortality 
for the world and by region from the prediction data obtained from GLOBOCAN 2012. 
For these models, time was modeled as 1, 2, 3, 4, and 5 corresponding to years 2010, 
2015, 2020, 2025, 2030, so the slope of the regression line can be interpreted as a 5 
year increase in the outcome variable.  
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Chapter III 
 
Predictive global trends in the incidence and mortality of pancreatic cancer based 
on geographic location, socio-economic status and demographic shift 
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INTRODUCTION 
In recent years, cancer control has been promoted as a global health priority.1-5 The 
global cancer burden (GCB) is rising at an alarming rate and is expected to nearly 
double by 2030.34-36 Pancreatic cancer (PC) is a lethal malignancy that accounts for 
about 4% of cancer-related deaths in both males and females worldwide.13-24 In the 
United States, PC accounts for about 2.7% of all new cancer cases and is projected to 
become the second largest cause of cancer-related deaths by 2030.25  
 Although the trends in the incidence and mortality of PC are well studied in the 
United States and some Western European countries, the same cannot be said for the 
rest of the world. There are few publications on pancreatic cancer originating from 
regions of low incidence or resource-poor areas of the world.28 Similarly, there is a 
scarcity of reports describing the overall global trends in the incidence and mortality of 
PC across all regions of the world and encompassing all strata of socio-economic 
development.  
The aim of this study is to describe the influence of geography (based on World 
Health Organization [WHO] regional classification), socio-economic development (based 
on Human Development Index [HDI]) and demographic shift on the global trends in the 
incidence and mortality of PC. The intent of the study was not to develop an independent 
model for predicting global cancer burden. It was aimed to review the predictive global 
trends of pancreatic cancer based on the comprehensive data available in GLOBOCAN 
2012 and present the results in a cogent fashion.  
 
RESULTS 
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Global PC Incidence and Mortality (for 2012) based on geography: worldwide and WHO 
regions (Table 1) 
The worldwide PC incidence including all ages and both sexes for 2012 is 
estimated at 337,872 with an age-standardized rate (ASR) of 4.2 per 100,000. The 
worldwide PC mortality including all ages and both sexes for 2012 is estimated at 
330,391 with an ASR of 4.0 per 100,000. Among the different regions, the WHO region 6 
(WPRO) is reported to have the highest incidence (113,015) whereas the highest 
mortality is noted in WHO region 4 (EURO- 111,029).  
 
Global PC Incidence and Mortality (for 2012) based socio-economic development (HDI) 
(Table 1)  
Comparison based on the four tier HDI model revealed striking differences in 
incidence and mortality rate between VHHD, HHD, MHD and LHD (Table 1). Both men 
and women from VHHD had much higher incidence and mortality (ASR) when compared 
to HHD, MHD and LHD regions.  
 
Global trends (2010-2030) in PC Incidence based on geography: worldwide and WHO 
regions (Figure 1a)   
Linear regression model was used to describe the trends in total PC incidence. 
We noted a statistically significant increase in incidence of PC for the entire world 
(p<0.001) with an average of 51,770 new cases every 5 years. Subset analysis for the 
WHO regions again revealed a statistically significant increase in the incidence for all six 
regions (p<0.001) with the most significant increases affecting region 6 (WPRO).  
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Global trends (2010-2035) in PC Mortality based on geography: worldwide and WHO 
regions (Figure 1 b)  
We noted a statistically significant increase in PC mortality for the entire world 
(p<0.001) with an average of 50,519 deaths every 5 years. Subset analysis for the WHO 
regions also revealed a statistically significant increase in the PC-related mortality for all 
six regions (p<0.001) with the most significant increases affecting region 6 (WPRO). The 
prediction data used for the linear regression analysis were obtained from GLOBOCAN 
for the global trends in incidence and mortality of PC (2010 – 2030) and are included in 
Supplemental Table 1.  
 
Effect of demographic change in PC incidence and mortality based on geography: for all 
WHO Regions (Figures 2a and 2b) 
Figure 2a shows the estimated combined number of new cases for Regions 1-6 
(for all ages; ages <65 and ages ≥ 65) for PC between 2012 and 2030. It is observed 
that the demographic shift in the total population will have a major influence on the 
projected incidence of PC in 2030 due to an increase in the number of adults 65 years 
and older. In addition to the rise in global PC incidence due to the demographic 
changes, we also observed a similar substantial increase in PC mortality due to the 
increase in the number of adults 65 years and older (Figures 2b).  
 
Effect of demographic change in PC incidence and mortality based on socio-economic 
development (HDI) (Figures 3 and 4) 
We determined the future burden of PC in 2030 by gender and demographics for 
the four levels of HDI on the basis of the rates in 2012. The Figures 3 and 4 and 
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Supplemental Table 2 provide trends of PC among VHHD, HDH, MDH and LHD. 
Overall, the highest incidence and mortality rates were observed for VHHD, followed by 
HDH, MDH and LDH.  
The influence of demographic shift on PC incidence and mortality revealed 
striking findings for different HDI regions. The demographic shift contributed to a greater 
rise in PC incidence and mortality for ages > 65 years in the regions of VHHD, HHD and 
MHD. In contrast, although we noted a rise in the incidence and mortality in the region of 
LHD for all ages, the increase predominantly affected the younger age group (< 65 years 
of age).  
 
DISCUSSION 
The results of our study demonstrate that the global burden of PC is predicted to 
rise significantly over the next 15 years. This rise in the global burden of PC is noted in 
all geographic regions of the world. Similarly, the increase affects all regions of the world 
regardless of the socio-economic development as noted by the rise in the burden in all 4 
HDI regions. This is alarming considering the progress in reducing the burden of many 
other cancers in some countries in the VHHD region.37 Kohler et al analyzed the data for 
the major cancers in the US (1992-2011) and noted a significant decrease in the 
incidence of prostate cancer (-2.5 to -10.5%), breast cancer (-0.4% to -2.2%) lung 
cancer (-1.9 to 4.8% for men and -1.1 to 2.5 % for women) and colorectal cancer (-2.6 to 
4.2% for men and -1.8% to -4.5%). Similarly, they noted a significant decrease in the 
mortality for several cancers such as lung (-1.1 to -2.9% for men and -0.8 to -1.9% for 
women), prostate (-0.5 to -4.1%), breast (-1.8 to -3.3%) and colorectum (-0.3 to -3.9% 
for men and -1 to -2.9% for women). The rise in the global burden of PC despite 
progress for other cancers in some parts of the world is a cause for concern.  
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We noted several points of interest in the rising global burden of PC. In 2012, 
region 6 (WPRO) and region 4 (EURO) accounted for the highest incidence and 
mortality. Over the next 15 years, although the incidence and mortality increases in all 
six regions, the rate of increase is not uniform. Whereas the PC related mortality is 
highest in region 4 (EURO) in 2012, this will be surpassed by region 6 (WPRO) over the 
next 15 years. The WPRO region with its 37 countries is home to nearly 1.8 billion 
people and consists of some of the world’s least developed countries in addition to some 
of the most rapidly emerging economies. Advance knowledge of these figures can help 
public policy and debate to allocate resources to tackle this lethal malignancy in the least 
developed countries.  
There was a significant association noted between PC and socio-economic 
status with the highest burden of PC seen in the VHHD countries. The ASR of PC 
incidence and mortality in VHHD countries is nearly six to seven fold higher than for the 
countries in the LHD strata. It is well known that there is a higher prevalence of the risk 
factors associated with PC (dietary and lifestyle choices) seen in the VHHD countries. It 
is likely that as more countries in the MHD and LHD regions transition to emerging 
economies with improving socio-economic conditions we may see a migration of these 
risk factors to those regions as well. Smoking, one of the most important risk factors for 
pancreatic cancer is on the rise in the developing countries which account for nearly 
70% of the global consumption.38 Obesity is another well-known risk factor for pancreatic 
cancer.39,40 Countries in the economic transition phase are also known to go through a 
nutrition transition phase with a rise in the rates of obesity. Popkin et al noted that 
reduced physical activity and dietary changes in the 1990’s have led to an increase in 
obesity rates in the developing countries.41  
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Kolkman et al performed a comparative study of the histo-pathologic type of 
esophageal cancer between a developed country (United States) and an emerging 
economy (India).42 Although squamous cell carcinoma is the predominant type of cancer 
in India, they noted a gradual increase in the rate of adenocarcinoma to correlate with 
increase in risk factors specific for esophageal adenocarcinoma such as obesity. There 
are several countries in the world that are in the zone of economic improvement, which 
could be affected by rising burden of PC. Knowledge of the risk factors can help steer 
public health measures that focus on increasing awareness and prevention.  
The correlation between age and PC burden showed mixed results. Advancing 
age (≥ 65) accounted for significant increases in PC incidence and mortality in VHHD, 
HHD and MHD countries. In contrast, the majority of the new cases and mortality related 
to PC in the LHD countries afflicts patients < 65 years of age and will continue to do so 
in the future. This age group in the LHD countries tends to be the main income earners 
and the rising PC burden in this segment can have significant adverse micro-economic 
and macro-economic consequences.  
In summary, the results of our study demonstrate that the global burden of PC is 
expected to rise significantly over the next 15 years. Although some regions may 
experience a disproportionate increase, the rise was noted in all regions of the world 
regardless of the location socio-economic status, age and gender. We noted a definite 
association between pancreatic cancer and higher socio-economic status, which may 
contribute, to a rise in the future burden in countries with emerging economies. The 
predilection for pancreatic cancer to affect younger populations in LHD countries can 
have significant micro and macro-economic adverse consequences. Advance 
knowledge of this data can help formulate strategies to specifically target countries and 
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populations and to also improvise public health policy to tackle this lethal disease on the 
global stage.  
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Figure 1: Trends in PC incidence (a) and mortality (b) based on worldwide and 
WHO regions 1-6. Time was modeled here as 1, 2, 3, 4, 5 corresponding to years 
2010, 2015, 2020, 2025, 2030, so the slope of the regression line can be interpreted 
as a 5 year increase in the outcome variable. 
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Figure 2. Effect of demographic change in PC incidence (a) and mortality (b) for 
combined WHO Regions 1-6.  
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Figure 3. Effect of demographic change in PC incidence and mortality for VHHD 
(a-b) and HHD (c-d).  
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Figure 4. Effect of demographic change in PC incidence and mortality for MHD (a-
b) and LHD (c-d).  
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Table 1. PC incidence and mortality statistics for 2012 based on worldwide, WHO 
regions 1-6 and HDI.  
Global pancreatic cancer burden based on geography: Worldwide and for the 6 WHO regions 
(2012) 
INCIDENCE 
Estimate
d 
incidenc
e, all 
ages 
 Popula
tion (all 
ages; 
both 
sex) 
 Population (all 
ages; male) 
 Populati
on (all 
ages; 
female) 
ASR (W) 
(all ages; 
both sex) 
ASR (W) 
(all ages; 
male) 
ASR (W) (all 
ages; female) 
World 337872 178161 159711 4.2 4.9 3.6 
Region 1 8324 4304 4020 1.8 2.0 1.6 
Region 2 75094 37016 38078 5.9 6.5 5.3 
Region 3 7686 4503 3183 1.9 2.2 1.5 
Region 4 110499 55795 54704 6.5 8.0 5.3 
Region 5 23210 12401 10809 1.5 1.7 1.3 
Region 6 113015 64116 48899 4.4 5.3 3.5 
 
MORTALITY 
Estimate
d 
mortality
, all ages 
 Popula
tion 
(both 
sex) 
 Population 
(male) 
 Populati
on 
(female) 
ASR (W) 
(both sex) 
ASR (W) 
(male) 
ASR (W) 
(female) 
World 330391 173827 156564 4.0 4.7 3.4 
Region 1 8048 4174 3874 1.7 2.0 1.5 
Region 2 73751 36477 37274 5.6 6.4 5.0 
Region 3 7440 4353 3087 1.8 2.1 1.5 
Region 4 111029 56350 54679 6.4 7.9 5.1 
Region 5 21638 11522 10116 1.4 1.5 1.2 
Region 6 108444 60926 47518 4.1 5.0 3.3 
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Global pancreatic cancer burden based on socio-economic development: For the 4 HDI 
regions (2012) 
INCIDENCE 
Estimated 
incidence, all 
ages 
 Populati
on (all 
ages; 
both sex) 
 Populati
on (all 
ages; 
male) 
 Populati
on (all 
ages; 
female) 
ASR (W) 
(all ages; 
both sex) 
ASR (W) 
(all ages; 
male) 
ASR (W) (all 
ages; female) 
Very High 
Human 
Development 
174344 87924 86420 7.2 8.5 6.1 
High Human 
Development 
55638 28491 27147 4.6 5.4 3.9 
Medium 
Human 
Development 
98632 56902 41730 2.7 3.3 2.2 
Low Human 
Development 
9108 4767 4341 1.2 1.4 1.1 
 
MORTALITY 
Estimated 
incidence, all 
ages 
 Populati
on (all 
ages; 
both sex) 
 Populati
on (all 
ages; 
male) 
 Populati
on (all 
ages; 
female) 
ASR (W) 
(all ages; 
both sex) 
ASR (W) 
(all ages; 
male) 
ASR (W) (all 
ages; female) 
Very High 
Human 
Development 
170497 85643 84854 6.8 8.0 5.6 
High Human 
Development 
56474 29254 27220 4.6 5.6 3.8 
Medium 
Human 
Development 
94447 54242 40205 2.6 3.2 2.1 
Low Human 
Development 
8822 4610 4212 1.2 1.3 1.1 
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PC= Pancreatic cancer 
ASR= Age standardized rate 
Region 1= AFRO (Africa) 
Region 2= PAHO (Americas) 
Region 3= EMRO (Eastern Mediterranean) 
Region 4= EURO (Europe) 
Region 5= SEARO (South East Asia) 
Region 6= WPRO (Western Pacific)  
HDI= Human Development Index 
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Chapter IV 
 
Global trends in liver cancer epidemiology based on geographic location, socio-
economic status and demographic shift. 
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INTRODUCTION 
Liver cancer (LC) is fast developing into a global medical crisis26. Historically, LC has 
been most prevalent in the developing regions of Southeast Asia and Africa. This high 
burden of LC in these developing regions has been mainly attributed to Hepatitis B virus 
(HBV) and exposure to aflotoxin27. However, in recent years, developed Western 
countries have witnessed an alarming rise in LC partly due to increased Hepatitis C virus 
(HCV) infection and non-communicable diseases (NCD) associated with alcohol use and 
non-alcoholic steatohepatitis (NASH)26. LC is the fifth most common cancer and the third 
leading cause of cancer-related deaths globally26,27.  
The trends in the incidence and mortality of LC have been well studied for certain 
developing regions of high incidence and few developed regions. However, there is 
scarcity of comprehensive reports unpinning the incidence and mortality trend for LC 
across all geographic regions and encompassing all strata of socio-economic 
development.  
The aim of this epidemiological study is to critically dissect the influence of geography 
(based on World Health Organization [WHO] regional classification), socio-economic 
development (based on Human Development Index [HDI]) and demographic shift on the 
global trends in the incidence and mortality of LC.  
 
RESULTS 
Global LC Incidence and Mortality (for 2012) based on geography: worldwide and WHO 
regions (Figure 1a,b) 
The worldwide LC incidence and mortality has been shown in Figure 1a. The 
global LC incidence including all ages and both sexes for 2012 is estimated at 782,451 
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with an age-standardized rate (ASR) of 10.1 per 100,000. The worldwide LC mortality 
including all ages and both sexes for 2012 is estimated at 745,533 with an ASR of 9.5 
per 100,000. Among the different regions, the WHO region 6 (WPRO) is reported to 
have both the highest incidence (500,506) and mortality (476,692) accounting for about 
64% of all LC incidence and mortality (Figure 1b).  
 
Global LC Incidence and Mortality (for 2012) based socio-economic development (HDI) 
(Figure 1b)  
Comparison based on the four tier HDI model revealed striking differences in 
incidence and mortality rate between VHHD, HHD, MHD and LHD (Figure 1b). The 
incidence and mortality of LC does not follow any particular socio-economic pattern. The 
MHD area has the highest incidence (531,931) and mortality (514,528) rates for all ages 
and both sexes combined. The VHHD areas are next with high incidence (153,946) and 
mortality (133,159) rates. The HHD and LHD areas have comparable incidence and 
mortality rates.  
Supplemental Table 1 shows the estimated LC incidence and mortality (2012) for 
worldwide and WHO regions and HDI areas for all ages for both male and female. 
Overall, the LC incidence and mortality is higher in male than female.  
 
Global LC 5-years prevalence (for 2012) based on geography: worldwide and WHO 
regions (Supplemental Figure 1a,b) 
The worldwide LC 5-years prevalence (proportions per 100,000) for male and 
female population has been shown in Supplemental Figure 1a. The global LC 5-years 
prevalence for male is estimated at 453,345 (proportion = 17.5%). The global LC 5-years 
	   34 
prevalence for female is estimated at 179,825 (proportion = 6.9%). Among the different 
regions, the WHO region 6 (WPRO) is reported to have both the highest 5-years 
prevalence for male (proportion = 41.9%) and female (proportion = 15.4%; Supplemental 
Figure 1b).  
 
Global LC 5-years prevalence (for 2012) based socio-economic development (HDI) 
(Supplemental Figure 1b)  
Comparison based on the four tier HDI model revealed an intriguing difference in 
the 5-years prevalence between VHHD, HHD, MHD and LHD (Supplemental Figure 1b). 
In contrast to the highest incidence and mortality rates discussed above for MHD area, 
the VHHD area has the highest 5-year prevalence for both male (proportion = 28.4%) 
and female (proportion = 11.7%). MHD area is second ranked with 5-year prevalence for 
both male (proportion = 20.7%) and female (proportion = 7.4%).  The HHD and LHD 
areas have comparable 5-years prevalence rates.  
 
Socio-economic variability within WPRO regional countries (Table 1, Supplemental 
Table 2a,b and Table 2) 
Table 1 lists the estimated LC incidence and mortality (2012) for all WPRO 
regional countries (for all ages; both sexes). It is observed that China contributed to 
about 84.5% and 86.3% of all WPRO incidence and mortality respectively. However, the 
ASR (worldwide) is higher than China (22.3) for several other WPRO countries including 
Mongolia (78.1), Lao PDR (52.6), Viet Nam (24.6) and Republic of Korea (22.8). 
Supplemental Table 2a shows the WPRO liver cancer estimates of incidence and 
mortality by different age groups. Interesting, the both male and female ages >= 75, the 
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rate of mortality is higher compared to the incidence. Supplemental Table 2b shows the 
top 6 WPRO member states LC estimates by age. An alarming observation is the 
relatively early onset of LC incidence and mortality for Mongolia and Lao PDR.   
Table 2 is the categorization of the different WPRO member states based on 
their HDI 2014 ranking, life expectancy, physician availability and health expenditure of 
the country. It is important to note that China as per Human Development Report 2014 is 
listed within the HHD category. China’s HDI increased over the past three decades from 
0.423 (1980) to 0.719 (2013). The GLOBOCAN 2012 estimates for incidence, mortality 
and trend predictions are based on data obtained prior to 2012 and have listed China 
within the MHD category. Within the WPRO countries, Australia and New Zealand are 
within the top 5 VHDD areas and has low incidence and mortality of LC [ASR(W) of 4.2 
and 4.0 respectively]. While the health expenditure (as % of GDP) in Australia and New 
Zealand is an impressive 9.0 and 10.1 respectively, areas with high LC incidence and 
mortality like China (5.2%), Mongolia (5.3%), Republic of Korea (7.2%), Cambodia 
(5.7%) have moderate level of health expenditure. Lao PDR, a low human development 
area has the lowest health expenditure at 2.8% and shows high ASR(W) and early onset 
of LC incidence and mortality. It is also important to note that the life expectancy at birth 
is significantly different within these WPRO countries based on socio-economic status.   
 
Global trends (2010-2030) in LC Incidence based on geography: worldwide and WHO 
regions (Figure 2a)   
Linear regression model was used to determine the trends in total LC incidence. 
We noted a statistically significant increase in incidence of LC for the entire world 
(p<0.0001) with an average of 117,075 new cases every 5 years. Subset analysis for the 
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WHO regions again revealed a statistically significant increase in the incidence for all six 
regions with the most significant increases affecting region 6 (WPRO; p<0.0001).  
 
Global trends (2010-2030) in LC Mortality based on geography: worldwide and WHO 
regions (Figure 2b)  
We noted a statistically significant increase in LC mortality for the entire world 
(p<0.0001) with an average of 112,160 deaths every 5 years. Subset analysis for the 
WHO regions also revealed a statistically significant increase in the LC-related mortality 
for all six regions (p<0.001) with the most significant increases affecting region 6 
(WPRO; p<0.0001). 
 
Effect of demographic change in LC incidence and mortality in WPRO Region (Figures 
3a,b) 
Figure 3a shows the estimated number of new cases for WPRO Region (for all 
ages; ages < 65 and ages ≥ 65 years) for LC between 2012 and 2030. It is observed that 
the demographic shift in the total population will have a major influence on the projected 
incidence of LC in 2030 due to an increase in the number of adults 65 years and older. 
In addition to the rise in LC incidence due to the demographic changes, we also 
observed a similar substantial increase in LC mortality in WPRO Region due to the 
increase in the number of adults 65 years and older (Figures 3b). It is important to note 
that the number of LC incidence for 2012 was higher in the younger population ages < 
65 years by more than 30,000. However, the predicted LC incidence is expected to shift 
towards the older population ages 65 years and older with an approximate increase of 
about 35,000 patients by 2030.   
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Effect of demographic change in LC incidence and mortality based on socio-economic 
development (HDI) (Supplemental Figures 2-5) 
We determined the future burden of LC in 2030 by gender and demographics for 
the four levels of HDI on the basis of the rates in 2012. The Supplemental figures 2 to 5 
provide trends of LC among VHHD, HHD, MHD and LHD. Overall, the highest incidence 
and mortality rates were observed for MHD, followed by VHDH, LDH and HDH. Thus, 
the demographic shift does not follow any particular socio-economic pattern.  
The influence of demographic shift on LC incidence and mortality revealed 
striking findings for different HDI regions. The demographic shift predicts a greater rise in 
LC incidence (227,282) and mortality (236,431) for adults older than ages 65 years in 
the regions of MHD area compared to 111,212 and 102,316 for incidence and mortality 
respectively for ages < 65 years. In contrast, although we noted a rise in the incidence 
(36,984) and mortality (35,122) in the region of LHD for all ages, the increase 
predominantly affected the younger age group (< 65 years of age).  
 
DISCUSSION 
The global burden of cancer is rising at a precarious rate and has been the leading 
cause of death worldwide1-5,34-36. Intriguingly, LC has catapulted itself as one of the 
deadliest forms being the second most-common case of cancer-related death 
worldwide26,27,29. As per the American Cancer Society, the 5-year relative survival rate 
after diagnosis is approximately 28% for localized, 7% for regional and 2% for distant 
metastasis43. The combined 5-year relative survival rate from LC is about 15% in US and 
about 12% in Europe43,44. One of the challenges for LC patients and clinicians is that LC 
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is not manifested during early stages and is often diagnosed at an advanced stage, 
thereby causing a poor 5-year relative survival rate.  
The results of our study demonstrate that the global burden of LC is predicted to 
rise significantly over the next 15 years. This rise in the global burden of LC is noted in 
all geographic regions of the world. However, the highest rate of LC incidence and 
mortality is observed in WPRO region accounting for about 64% of all LC incidence and 
mortality. The LC burden was second highest in SEARO, followed by EURO, PAHO and 
AFRO regions. Similarly, the increase affects all regions of the world regardless of the 
socio-economic development as noted by the rise in the burden in all 4 HDI regions. The 
highest LC burden was observed in the MHD areas. However, an interesting finding in 
this study is that 5-years prevalence of LC is highest in VHHD area (28.4% and 11.7% 
for male and female) compared to MHD (20.7% for male and 7.4% for female). 
Therefore, the incidence of LC is increasing at a higher proportion for the more 
developed/VHHD countries. Considering the progress VHHD countries have made 
towards reducing the cancer burden for several types of cancer37, the increase in the 5-
years prevalence of LC for both men and women are alarming and needs detailed 
analysis. In the annual report on cancer burden for major cancer types in the US (1992-
2011), Kohler et al noted a significant decrease in the incidence of prostate cancer (-2.5 
to -10.5%), colorectal cancer (-2.6 to 4.2% for men and -1.8% to -4.5%), lung cancer (-
1.9 to 4.8% for men and -1.1 to 2.5 % for women) and breast cancer (-0.4% to -2.2%). 
Similarly, they observed a significant decrease in the mortality for certain cancer types 
including breast (-1.8 to -3.3%), colorectum (-0.3 to -3.9% for men and -1 to -2.9% for 
women), lung (-1.1 to -2.9% for men and -0.8 to -1.9% for women) and prostate (-0.5 to -
4.1%). Therefore, the rise in the LC burden despite progress for other cancers in some 
parts of the world is a cause for concern.  
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We noted several points of interest in the rising global burden of LC in WPRO 
region. The WPRO region is consisting of 37 countries with a combined population of 
nearly 1.8 billion people. It consists of an mélange of world’s least developed countries 
in addition to some of the most rapidly emerging economies. As noted in Table 2, the 
HDI rankings of the member countries within WPRO regions span across all 4 HDI areas 
and spreads across Australia (VVHD rank 2nd) to Solomon Islands and Papua New 
Guinea (LHD rank 157th). Therefore, advanced knowledge of these figures can help 
public policy and debate to allocate resources to tackle this lethal malignancy in the least 
developed countries.  
We did not observe a significant association between LC and socio-economic 
status with the highest burden of LC seen in the MHD countries. The ASR of LC 
incidence and mortality in MHD countries is > 2 fold greater than for the countries in the 
VHHD and LHD strata and >3 fold greater than HHD countries. It is well known that 
there is a higher prevalence of the risk factors associated with LC (dietary and lifestyle 
choices) seen in the MHD, HHD and VHHD countries. It is likely that as more countries 
in the LHD regions transition to emerging economies with improving socio-economic 
conditions we may see a migration of some of these risk factors to those regions as well. 
Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) are the strongest 
risk factors for hepatocellular carcinoma (HCC), the histological type that is responsible 
for majority of LC worldwide. HCC can develop after many years of infection with either 
of these viruses. HBV and HCV are both highly contagious diseases that can be passed 
from person to person through blood (such as by sharing needles) or sexual contact. 
There is strong evidence of the association of obesity (high BMI), long term consumption 
of alcoholic drinks (three or more per day) and heavy exposure to aflatoxins (toxins 
secreted by certain fungi) with the development of LC. Aflatoxins are produced mainly 
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due to improper storage of food in warmer climatic regions of the world. Major foods that 
are contaminated by aflatoxins include various types of nuts including peanuts, 
pistachios, and Brazil nuts. Other common contaminating food includes grains, chilies, 
black pepper and dry fruits. Aflatoxin exposure accentuates the development of HCC 
from HBV infection and has been partly contained with better storage of grains. Dietary 
and lifestyle modifications in several developing countries has been able to reduce 
obesity and diabetes, which are associated with HCV-infected population. As per the 
emerging 2015 reports from the World Cancer Research Fund International – 
Continuous Update Project (CUP), limited reports have shown that higher consumption 
of fish and regular physical activity decreases the risk of LC.  
The correlation between age and LC burden showed mixed results. Advancing 
age (≥ 65) accounted for significant increases in LC incidence and mortality in MHD, 
HHD and VHHD countries. In contrast, the majority of the new cases and mortality 
related to LC in the LHD countries afflicts patients < 65 years of age and will continue to 
do so in the future. This age group in the LHD countries tends to be the main income 
earners and the rising LC burden in this segment can have significant adverse micro-
economic and macro-economic consequences.  
In summary, the results of our study demonstrate that the global burden of LC is 
expected to rise significantly over the next 15 years. Although the WPRO region may 
experience a disproportionate increase, the rise was noted in all regions of the world 
regardless of the location, socio-economic status, age and gender. We did not observe a 
definite association between LC and higher socio-economic status, which may be 
associated with variable risk factors. The predilection for LC to affect younger 
populations in LHD countries can have significant micro and macro-economic adverse 
consequences. Advance knowledge of this data can help formulate strategies to 
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specifically target countries and populations and to also improvise public health policy to 
tackle this lethal disease on the global stage.  
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Figure 1: LC incidence and mortality worldwide by WHO and HDI classification (for 
all ages and both sexes) 
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Figure 2a,b: Time Trend in liver cancer incidence and mortality for WHO regions 
2010 – 2030. Time was modeled here as 1, 2, 3, 4, 5 corresponding to years 2010, 
2015, 2020, 2025, 2030, so the slope of the regression line can be interpreted as a 
5 year increase in the outcome variable.  
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Figure 3a,b: Effect of demographic shift on the incidence (a) and mortality (b) 
rates in WPRO regions (2012 – 2030)  
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Table 1: LC incidence and mortality in WPRO region 6 (for both sexes; all ages) 
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Table 2: Categorization of WPRO regional members based on HDI rank, life 
expectancy, physicians and health expenditure.   
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Supplemental Figure 1a,b: LC estimated incidence and 5-year prevalence 
(proportion) worldwide by WHO and HDI classification for male (a) and female (b) 
of all ages 
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Supplemental Figure 2a,b: Effect of demographic shift on the incidence (a) and 
mortality (b) rates in MDH areas (2012 – 2030)  
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Supplemental Figure 3: Effect of demographic shift on the incidence and mortality 
rates in LDH areas (2012 – 2030)  
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Supplemental Figure 4a,b: Effect of demographic shift on the incidence (a) and 
mortality (b) rates in VHHD areas (2012 – 2030)  
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Supplemental Figure 5a,b: Effect of demographic shift on the incidence (a) and 
mortality (b) rates in HHD areas (2012 – 2030)  
 
 
 
 
 
 
 
 
 
	   52 
Supplemental Table 1: LC incidence and mortality worldwide by WHO and HDI 
classification (for male and female; all ages) 
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Supplemental Table 2a,b: LC incidence and mortality in WPRO region 6 by age (for 
male and female) (a). LC incidence and mortality in TOP 6 WPRO member states 
by age (for both sexes) (b) 
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Chapter V 
Summary  
The time trends in cancer incidence and mortality vary substantially for different 
countries. The cancer transition in low-and medium-HDI countries combined with 
growing and ageing population means that many countries are facing a double burden of 
cancer – that is the burden associated with infectious agents combined with an 
increasingly westernized lifestyle. The global cancer burden is expected to increase in all 
countries due to population growth, aging, and an increasing prevalence of certain risk 
factors. This outstanding global health concern has been well responded by the health 
community through the endorsement of the “25 by 25” strategy as part of the NCD 
Global Monitoring Framework. The goal of the NCD Global Health Framework is to 
reduce avoidable mortality from NCDs by 25% by 2025 through the support and active 
participation from all levels of society.45 The “25 by 25” strategy would be expected to 
represent a decrease of 25% premature cancer deaths each year by 2025 (a reduction 
of 1.5 Million from a predicted 6 Million premature cancer deaths in people aged 30-69 
years). The achievement of the 25% reduction in premature cancer deaths will need 
more effective prevention, to reduce incidence, and more effective health systems, to 
improve survival. As aptly put forth by Drs. Paolo Vineis and Christopher P Wild, “Cancer 
is a global and growing, but not uniform, problem.”7 The primary prevention of cancer is 
the effective and cost-effective way to fight the war against cancer with 33% to 50% of 
cancers that are preventable. The progress of cancer control strongly depends on the 
complementation of cancer prevention with early detection and effective treatments. 
Unfortunately, the current socio-economic trends globally do not promote prevention 
since it takes time to manifest and lacks strong leadership/policy advocates.  
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Final thoughts 
A topic of continuous global health debate is the usefulness to identify differences in 
cancer incidence and mortality trends between countries, between regions within a 
country, or between populations defined by racial or ethnic group or socio-economic 
status. The concern put forth is that whether the differences noted above have any effect 
on the health policy or the public especially because the countries being compared have 
widely different economic development, some of them extremely poor, others with civil 
conflicts. Anderson and colleagues1 have put forth hypothesis that the information on the 
global trends and disparities in cancer burden can help focus debate on reducing 
geographical, racial and/or ethnic disparities. Groundbreaking research by Bray and 
colleagues46 have demonstrated that long term surveillance of worldwide trends in 
cancer incidence has provided data for causal research and the basis for prevention and 
screening. It is expected that the continuous global surveillance of cancer would provide 
an impetus for alteration in healthcare policy and healthcare systems and serve as a key 
metric for the global cancer control.  
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